Our results raised the further question of whether the transcription signature of VHL, SETD2, PBRM1 and BAP1 as a molecular marker has a valuable potential in ccRCC molecular diagnostics. This evidence concerns the gene SETD2 and nonpapillary renal cell carcinoma.